1. Home
  2. RVMD vs LYFT Comparison

RVMD vs LYFT Comparison

Compare RVMD & LYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMD
  • LYFT
  • Stock Information
  • Founded
  • RVMD 2014
  • LYFT 2007
  • Country
  • RVMD United States
  • LYFT United States
  • Employees
  • RVMD N/A
  • LYFT N/A
  • Industry
  • RVMD Biotechnology: Biological Products (No Diagnostic Substances)
  • LYFT Business Services
  • Sector
  • RVMD Health Care
  • LYFT Consumer Discretionary
  • Exchange
  • RVMD Nasdaq
  • LYFT Nasdaq
  • Market Cap
  • RVMD 7.5B
  • LYFT 8.0B
  • IPO Year
  • RVMD 2020
  • LYFT 2019
  • Fundamental
  • Price
  • RVMD $65.84
  • LYFT $24.64
  • Analyst Decision
  • RVMD Strong Buy
  • LYFT Buy
  • Analyst Count
  • RVMD 17
  • LYFT 31
  • Target Price
  • RVMD $77.24
  • LYFT $22.36
  • AVG Volume (30 Days)
  • RVMD 2.4M
  • LYFT 19.1M
  • Earning Date
  • RVMD 11-05-2025
  • LYFT 11-05-2025
  • Dividend Yield
  • RVMD N/A
  • LYFT N/A
  • EPS Growth
  • RVMD N/A
  • LYFT N/A
  • EPS
  • RVMD N/A
  • LYFT 0.36
  • Revenue
  • RVMD N/A
  • LYFT $6,273,827,000.00
  • Revenue This Year
  • RVMD N/A
  • LYFT $14.28
  • Revenue Next Year
  • RVMD $537.73
  • LYFT $13.14
  • P/E Ratio
  • RVMD N/A
  • LYFT $67.72
  • Revenue Growth
  • RVMD N/A
  • LYFT 14.90
  • 52 Week Low
  • RVMD $29.17
  • LYFT $9.66
  • 52 Week High
  • RVMD $65.98
  • LYFT $25.54
  • Technical
  • Relative Strength Index (RSI)
  • RVMD 84.78
  • LYFT 71.54
  • Support Level
  • RVMD $58.91
  • LYFT $19.44
  • Resistance Level
  • RVMD $63.15
  • LYFT $22.19
  • Average True Range (ATR)
  • RVMD 2.19
  • LYFT 1.01
  • MACD
  • RVMD 0.40
  • LYFT 0.46
  • Stochastic Oscillator
  • RVMD 98.46
  • LYFT 85.42

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

About LYFT Lyft Inc.

Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.

Share on Social Networks: